NRMGX
Price
$17.59
Change
+$0.02 (+0.11%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

NRMGX vs RPTIX

Header iconNRMGX vs RPTIX Comparison
Open Charts NRMGX vs RPTIXBanner chart's image
Neuberger Berman Mid Cap Growth R6
Price$17.59
Change+$0.02 (+0.11%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
NRMGX vs RPTIX Comparison Chart
Loading...
VS
NRMGX vs. RPTIX commentary
Sep 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NRMGX is a Buy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. NRMGX (1.74B). RPTIX pays higher dividends than NRMGX: RPTIX (0.18) vs NRMGX (0.00). NRMGX was incepted earlier than RPTIX: NRMGX (12 years) vs RPTIX (9 years). NRMGX is a more actively managed with annual turnover of: 101.00 vs. RPTIX (21.70). NRMGX has a lower initial minimum investment than RPTIX: NRMGX (0) vs RPTIX (500000). NRMGX annual gain was more profitable for investors over the last year : 27.32 vs. RPTIX (14.81). RPTIX return over 5 years is better than : 15.09 vs. NRMGX (12.51).
NRMGXRPTIXNRMGX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years9 years-
Gain YTD16.6679.127183%
Front LoadN/AN/A-
Min. Initial Investment0500000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.74B31.4B6%
Annual Yield % from dividends0.000.18-
Returns for 1 year27.3214.81184%
Returns for 3 years-21.56-13.57159%
Returns for 5 years12.5115.0983%
Returns for 10 years23.01N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp